跳至主要内容
临床试验/NCT01167972
NCT01167972已完成不适用

Observational Study on the Management of Patients With Non Small Cell Lung Cancer (NSCLC) Adenocarcinoma Tested for the Activating Mutation of Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR TK)

AstraZeneca1 个研究点 分布在 1 个国家目标入组 2,000 人开始时间: 2010年9月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
AstraZeneca
入组人数
2,000
试验地点
1
主要终点
The main objective of the study is to determine the proportion of patients with M + mutation status among patients with NSCLC adenocarcinoma

研究概览

简要总结

The main objective of the study is to determine the proportion of patients with M + mutation status among patients with Non Small Cell Lung Cancer adenocarcinoma.

详细描述

MSD

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient with lung cancer (Non Small Cell Lung Cancer adenocarcinoma)
  • Patient for whom a search for the mutational status of EGFR (EGFR-M +, M- or Mx) has been done or is being analyzed

排除标准

  • Assessment of mutational status of EGFR is not done

结局指标

主要结局

The main objective of the study is to determine the proportion of patients with M + mutation status among patients with NSCLC adenocarcinoma

时间窗: At baseline

次要结局

  • Describe the therapeutic management according to the mutational status (EGFR M +, EGFR M- and Mx).(12 months / At each visit)
  • Describe the therapeutic management of patients with EGFR M +.(12 months / At each visit)
  • Describe the clinical course of patients EGFR-M +, treated for first-line treatment, and then 2nd line treatment, until 31-AUG-2012(12 months / At each visit)

研究者

发起方
AstraZeneca
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验